Avonex market forecast points to steady growth through 2030

The global Avonex market is projected to rise from $1.95 million in 2025 to $2.58 million by 2030, driven by growing multiple sclerosis diagnoses and continued demand for long-term injectable therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest in the years ahead.

Why it matters: - Avonex remains a relevant therapy option as multiple sclerosis cases rise and demand grows for long-term disease-modifying treatments. - The market’s projected expansion signals continued use of interferon beta therapies despite broader shifts in MS care. - The report also points to regional growth opportunities, especially in Asia-Pacific.

What happened: - The Business Research Company released its Avonex Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the Avonex market will grow from $1.95 million in 2025 to $2.07 million in 2026. - The report projects the market will reach $2.58 million by 2030. - The forecast period implies a 5.7% CAGR from 2026 to 2030. - North America held the largest share of the Avonex market in 2025. - Asia-Pacific is forecast to be the fastest-growing regional market.

The details: - Avonex is the brand name for interferon beta-1a. - The drug is primarily prescribed for relapsing forms of multiple sclerosis. - Avonex is designed to reduce relapse frequency and slow physical disability progression. - Avonex functions as an immunomodulator that lowers inflammation and helps limit nerve damage. - Historical growth was supported by early approvals of interferon beta therapies. - Other drivers included rising MS diagnoses, the limited availability of oral MS treatments in the past, Avonex’s established safety profile, and neurologists’ familiarity with interferon-based medications. - Forward growth is expected to be supported by a larger MS patient population, demand for stable long-term therapies, more specialty neurology clinics, improved injection devices, and ongoing reimbursement support. - The report highlights continued use of interferon therapies, a shift toward long-term disease-modifying treatment, preference for weekly injectable regimens, early intervention in MS, and expanded patient adherence programs. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report additions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The report includes a free sample download: Download the sample report. - The full report is available here: View the full market report.

Between the lines: - Rising MS prevalence is the clearest demand signal behind the forecast. - The UK example in the release shows how diagnosis growth is not evenly distributed, which can shape treatment demand by region. - The emphasis on weekly injectable regimens suggests Avonex still has a defined niche even as MS treatment options broaden. - North America’s lead likely reflects stronger awareness and healthcare infrastructure, while Asia-Pacific’s growth outlook points to expanding diagnosis and specialty care access.

What's next: - The market will likely track MS diagnosis trends, reimbursement conditions, and the pace of specialty care expansion. - Product positioning may continue to center on adherence support, injection-device improvements, and long-term therapy use. - Regional competition may intensify as Asia-Pacific access to MS care improves.

The bottom line: - Avonex is in a modest but steady growth phase, with rising MS prevalence and durable demand for established injectable therapies supporting the market through 2030.